Laura M.C. Welschen
VU University Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Laura M.C. Welschen.
Diabetes Care | 2011
Hata Zavrelova; Trynke Hoekstra; Marjan Alssema; Laura M.C. Welschen; Giel Nijpels; Annette C. Moll; Henrica C.W. de Vet; Bettine C. P. Polak; Jacqueline M. Dekker
OBJECTIVE To identify distinct developmental patterns of diabetic retinopathy (DR) and assess the risk factor levels of patients in these clusters. RESEARCH DESIGN AND METHODS A cohort of 3,343 patients with type 2 diabetes mellitus (T2DM) monitored and treated in the Diabetes Care System West-Friesland, the Netherlands, was followed from 2 to 6 years. Risk factors were measured, and two-field fundus photographs were taken annually and graded according to the EURODIAB study group. Latent class growth modeling was used to identify distinct developmental patterns of DR over time. RESULTS Five clusters of patients with distinct developmental patterns of DR were identified: A, patients without any signs of DR (88.9%); B, patients with a slow regression from minimal background to no DR (4.9%); C, patients with a slow progression from minimal background to moderate nonproliferative DR (4.0%); D, patients with a fast progression from minimal or moderate nonproliferative to (pre)proliferative or treated DR (1.4%); and E, patients with persistent proliferative DR (0.8%). Patients in clusters A and B were characterized by lower risk factor levels, such as diabetes duration, HbA1c, and systolic blood pressure compared with patients in progressive clusters (C–E). CONCLUSIONS Clusters of patients with T2DM with markedly different patterns of DR development were identified, including a cluster with regression of DR. These clusters enable a more detailed examination of the influence of various risk factors on DR.
BMC Public Health | 2010
Abeer Ahmad; Jacqueline G. Hugtenburg; Laura M.C. Welschen; Jacqueline M. Dekker; Giel Nijpels
BackgroundDrug related problems (DRPs) are common among elderly patients who are discharged from the hospital and are using several drugs for their chronic diseases. Examples of drug related problems are contra-indications, interactions, adverse drug reactions and inefficacy of treatment. Causes of these problems include prescription errors and non-compliance with treatment. The aim of this study is to examine the effect of medication review and cognitive behaviour therapy of discharged patients by community pharmacists to minimize the occurrence of drug related problems.Methods/DesignA randomized controlled trial will be performed. Community pharmacists will be randomized into a control group and an intervention group. 342 Patients, aged over 60 years, discharged from general and academic hospitals, using five or more prescription drugs for their chronic disease will be asked by their pharmacy to participate in the study.Patients randomized to the control group will receive usual care according to the Dutch Pharmacy Standard. The medication of patients randomised to the intervention group will be reviewed by the community pharmacist with use of the national guidelines for the treatment of diseases, when patients are discharged from the hospital. The Pharmaceutical Care network Europe Registration form will be used to record drug related problems. Trained pharmacy technicians will counsel patients at home at baseline and at 1,3,6,9 and 12 months, using Cognitive Behaviour Treatment according to the Theory of Planned Behaviour. The patients attitude towards medication and patients adherence will be subject of the cognitive behaviour treatment. The counselling methods that will be used are motivational interviewing and problem solving treatment. Patients adherence towards drug use will be determined with use of the Medication Adherence Report Scale Questionnaire. There will be a follow-up of 12 months.The two primary outcome measures are the difference in occurrence of DRPs between intervention and control group and adherence with drug use. Secondary endpoints are attitude towards drug use, incidence of Re-hospitalisations related to medicines, functional status of the patient, quality of life and the cost-effectiveness of this intervention.DiscussionCombining both medication review and Cognitive Behaviour Treatment may decrease DRPs and may result in more compliance with drug use among patients discharged from the hospital and using 5 or more chronic drugs.Trial registrationDutch Trial Register NTR1194
Diabetes Care | 2012
Laura M.C. Welschen; Sandra D. M. Bot; Piet J. Kostense; Jacqueline M. Dekker; Danielle R.M. Timmermans; Trudy van der Weijden; Giel Nijpels
OBJECTIVE Patients with type 2 diabetes mellitus (T2DM) underestimate their risk of developing severe complications, and they do not always understand the risk communication by their caregivers. The aim of this study was to investigate the effects of an intervention focused on the communication of the absolute 10-year risk of developing cardiovascular disease (CVD) in patients with T2DM. RESEARCH DESIGN AND METHODS A randomized controlled trial was performed in T2DM patients newly referred to the Diabetes Care System (DCS) West-Friesland, a managed-care system in the Netherlands. The intervention group (n = 131) received a six-step CVD risk communication. Control subjects (n = 130) received standard managed care. The primary outcome measure was appropriateness of risk perception (difference between actual CVD risk calculated by the UK Prospective Diabetes Study risk engine and risk perception). Secondary outcome measures were illness perceptions, attitude and intention to change behavior, satisfaction with the communication, and anxiety and worry about CVD risk. Patients completed questionnaires at baseline, at 2 weeks (immediately after the intervention), and at 12 weeks. RESULTS Appropriateness of risk perception improved between the intervention and control groups at 2 weeks. This effect disappeared at 12 weeks. No effects were found on illness perceptions, attitude and intention to change behavior, or anxiety and worry about CVD risk. Patients in the intervention group were significantly more satisfied with the communication. CONCLUSIONS This risk communication method improved patients’ risk perception at 2 weeks but not at 12 weeks. Negative effects were not found, as patients did not become anxious or worried after the CVD risk communication.
Pharmacoepidemiology and Drug Safety | 2011
Egbert J.F. Lamberts; Giel Nijpels; Laura M.C. Welschen; Jacqueline G. Hugtenburg; Jacqueline M. Dekker; Patrick C. Souverein; Marcel L. Bouvy
The benefits of intensive and continuous antihyperglycemic drug therapy have been extensively described. Data on long‐term patterns and modifications of antihyperglycemic drug use are scarce however. Moreover randomized controlled studies may not reflect actual drug use in daily clinical practice.
Diabetes-metabolism Research and Reviews | 2012
Egbert J.F. Lamberts; Giel Nijpels; Laura M.C. Welschen; Jacqueline G. Hugtenburg; Jacqueline M. Dekker; Patrick C. Souverein; Marcel L. Bouvy
Statins play an important role in the prevention of cardiovascular disease in type 2 diabetes. Several studies have reported low adherence with statins among patients with type 2 diabetes. Studies comparing discontinuation of statins compared with discontinuation of oral anti‐diabetics within the same individuals before and after initiation of oral anti‐diabetic drugs are not available. The aim of this study was to describe discontinuation among patients with type 2 diabetes prescribed statins prior to and after initiation of oral anti‐diabetics and to compare statin discontinuation with discontinuation of oral anti‐diabetics.
Diabetologia | 2010
H. Zavrelova; Trynke Hoekstra; Marjan Alssema; Laura M.C. Welschen; G. Nijpels; Annette C. Moll; Bettine C. P. Polak; J. M. Dekker
Background and aims: The association between type 2 diabetes and different forms of cognitive impairment is well established. The mechanism behind the association is however still unrevealed. We ha ...
Diabetes Care | 2005
Laura M.C. Welschen; Evelien Bloemendal; Giel Nijpels; Jacqueline M. Dekker; Robert J. Heine; W.A.B. Stalman; L.M. Bouter
Cochrane Database of Systematic Reviews | 2012
Laura M.C. Welschen; Evelien Bloemendal; Giel Nijpels; Jacqueline M. Dekker; Robert J. Heine; W.A.B. Stalman; L.M. Bouter
BMC Public Health | 2007
Laura M.C. Welschen; Patricia van Oppen; Jacqueline M. Dekker; L.M. Bouter; W.A.B. Stalman; Giel Nijpels
Journal of Behavioral Medicine | 2013
Laura M.C. Welschen; Patricia van Oppen; Sandra D. M. Bot; Piet J. Kostense; Jacqueline M. Dekker; Giel Nijpels